companydata.dkEvaxion A/S
CVR: 31762863
Secondary names: NOVVAC A/S, EVAXION BIOTECH A/S
Previous names: NOVVAC ApS, EVAXION BIOTECH ApS, EVAXION BIOTECH A/S
Evaxion A/S is currently facing significant financial challenges, as evidenced by its declining equity and substantial losses over the past few years. In 2024, the company reported revenue of 22.3 million DKK but incurred a loss of 73.3 million DKK, following a sharp decline in revenue from 507,000 DKK in 2023 and a loss of 152.4 million DKK. The equity position has deteriorated from 212.8 million DKK in 2021 to -11.8 million DKK in 2024, raising concerns about its financial stability. While the company operates in the research and experimental development sector, its current trajectory suggests a need for strategic restructuring to improve profitability and restore investor confidence.
AI-generated summary
Overview
Details
Contact
Advertising protectedPurpose
Virksomhedens formål er at skabe avanceret software med henblik på udvikling af nye immunterapier og vacciner.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 22.3 mio. | -73.3 mio. | 94.7 mio. | -11.8 mio. | 46 | |
History
Ownership
Management
Directors
Board
Production units (1)
Similar companies
Companies in the same industry and area